oligonucleotide microarray hybridization (Veracyte Inc)
Structured Review
![Association of immune marker signatures with PSA response and OS. (A) The correlations between the 24 non-redundant (ie, those without high Spearman correlations among each other) set of evaluated tumor immune microenvironment gene expression signatures (ρ is shown), (B) OS of the group with tumor immune gene expression signature analysis is not significantly different from the overall cohort of Lu-PSMA therapy treated patients at our institution and (C) the <t>cDNA</t> yield from RNA extracted from tumor samples, best PSA response and relative expression signature level (z-scores, higher values indicate higher signature) of immune-related gene signatures are shown correspondingly to identify patterns of signatures with regard to PSA response. Patients with higher PD-L2 signature (above the median) have longer OS time (D) and greater PSA responses (E). Lu-PSMA, [ 177 Lu]Lutetium-PSMA-617; mo., months; OS, overall survival; PD-L1, programmed death-ligand 1; PSA, prostate-specific antigen.](https://pub-med-central-images-cdn.bioz.com/pub_med_central_ids_ending_with_3337/pmc10603337/pmc10603337__jitc-2023-007354f01.jpg)
Oligonucleotide Microarray Hybridization, supplied by Veracyte Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/oligonucleotide microarray hybridization/product/Veracyte Inc
Average 90 stars, based on 1 article reviews
Images
1) Product Images from "Analysing the tumor transcriptome of prostate cancer to predict efficacy of Lu-PSMA therapy"
Article Title: Analysing the tumor transcriptome of prostate cancer to predict efficacy of Lu-PSMA therapy
Journal: Journal for Immunotherapy of Cancer
doi: 10.1136/jitc-2023-007354
Figure Legend Snippet: Association of immune marker signatures with PSA response and OS. (A) The correlations between the 24 non-redundant (ie, those without high Spearman correlations among each other) set of evaluated tumor immune microenvironment gene expression signatures (ρ is shown), (B) OS of the group with tumor immune gene expression signature analysis is not significantly different from the overall cohort of Lu-PSMA therapy treated patients at our institution and (C) the cDNA yield from RNA extracted from tumor samples, best PSA response and relative expression signature level (z-scores, higher values indicate higher signature) of immune-related gene signatures are shown correspondingly to identify patterns of signatures with regard to PSA response. Patients with higher PD-L2 signature (above the median) have longer OS time (D) and greater PSA responses (E). Lu-PSMA, [ 177 Lu]Lutetium-PSMA-617; mo., months; OS, overall survival; PD-L1, programmed death-ligand 1; PSA, prostate-specific antigen.
Techniques Used: Marker, Gene Expression, Expressing
